BJERKHOLT ERIC sold $469K of MIRM
BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) sold 5,000 shares of Mirum Pharmaceuticals, Inc. (MIRM) at an average of $93.82 ($92.84–$95.12, $0.47M total) across 3 trades on 2026-06-08 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete, dated record of insider selling (CFO, open-market) and the post-trade share count, but does not include new operational or financial guidance.
Market read
Traders may monitor insider activity as a sentiment/positioning input, but 10b5-1 structure usually limits fundamental interpretation.
What to watch
Check for clustering of insider sales across recent Form 4s and whether any concurrent institutional ownership changes occurred; a single 10b5-1 sale is often low-signal.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for Mirum Pharmaceuticals, Inc.
Ticker impact
Mirum Pharmaceuticals CFO Eric Bjerkholt sold $469,077 of MIRM shares via an open-market sale under a 10b5-1 plan on June 8.
Near-term impact likely minimal; any reaction would be more about positioning/flow than new company fundamentals.
This is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight as a fresh bearish catalyst.
Market effects
No direct sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than negative expectations; traders may ignore it unless paired with other negative catalysts.
Key entities
- issuerMirum Pharmaceuticals, Inc.
Company whose CFO disclosed an open-market sale of shares via a pre-arranged 10b5-1 plan.
- insiderEric BJERKHOLT
Chief Financial Officer who sold 5,000 shares on June 8, 2026.
